Personalized mRNA skin cancer therapy achieves success in late-stage clinical trial
Pharmaceutical companies Merck and Moderna announced positive Phase 3 trial results for an individualized melanoma treatment designed with artificial intelligence. Algorithms examine each patient's blood and tumor mutations to target specific proteins, creating a tailored vaccine administered alongside standard immunotherapy.
